Cell Therapeutics (NASDAQ: [[ticker:CTIC]]), the Seattle-based developer of pixantrone for non-Hodgkin’s lymphoma, said today that the experimental treatment will be reviewed by an FDA advisory panel on February 10. The FDA’s Oncologic Drugs Advisory Committee will review the evidence for pixantrone and make a recommendation to the agency, which will ultimately decide whether to clear the drug for sale in the U.S. The FDA’s deadline for completing its review of the product is April 23.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
